Quote | Lexaria Bioscience Corp. Warrant (NASDAQ:LEXXW)
Last: | $1.05 |
---|---|
Change Percent: | 24.06% |
Open: | $1.0252 |
Close: | $1.05 |
High: | $1.05 |
Low: | $1 |
Volume: | 1,829 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | Lexaria Bioscience Corp. Warrant (NASDAQ:LEXXW)
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs ...
--News Direct-- Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? Kelowna, British Columbia – May 17, 2024 – TheNewswire – Lexaria Biosc...
Message Board Posts | Lexaria Bioscience Corp. Warrant (NASDAQ:LEXXW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Warrant Company Name:
LEXXW Stock Symbol:
NASDAQ Market:
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs ...
--News Direct-- Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? Kelowna, British Columbia – May 17, 2024 – TheNewswire – Lexaria Biosc...
Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, has proven in numerous studies the ability of its patented DehydraTECH(TM) technology to increase bio-absorption compared to standard industry formulations, as well as reduce time of onset and deliver drugs m...